<h1>Complex peptide licensing: Kashiv to register and supply; Intas/Accord to commercialize in India, Europe and the UK.</h1> An exclusive licensing and supply agreement assigns Kashiv responsibility for regulatory registration, manufacturing and supply of a complex peptide product, while Intas will commercialize in India and Accord will commercialize and distribute in Europe and the UK, allocating territorial rights and distinct regulatory, supply and commercial roles between the parties.